While the United States, Canada and Mexico are reporting overall reductions in Covid-19 cases and deaths, new infections are increasing in the rest of the Americas, Pan American Health Organization (PAHO) Director Carissa Etienne said.

Covid-19 has caused 6.9 million deaths globally, more than double what official numbers show, according to an analysis by the Institute for Health Metrics and Evaluation (IHME) at the University of Washington School of Medicine. IHME found that Covid-19 deaths are significantly underreported in almost every country.

Novavax Inc. said on April 5 participants in the company’s Covid-19 vaccine trials in South Africa and the UK can receive additional shots, ensuring those who received a placebo can also get the active vaccine.

Drug developer Novavax Inc. completed enrolling 30,000 volunteers in a late-stage study of the company’s Covid-19 vaccine in the United States and Mexico.

Novavax announced a Memorandum of Understanding (MOU) with Gavi, the Vaccine Alliance, to provide 1.1 billion doses of the company’s Covid-19 vaccine candidate NVX-CoV2373 for the COVAX Facility.

Mexico surpassed India in confirmed Covid-19 deaths on Jan. 29, giving the Latin American country the third-highest toll worldwide, according to a Reuters tally of official data.

More than 1 million people have died from Covid-19 in North and South America, the Pan American Health Organization (PAHO) said.

Novavax Inc. started a large late-stage study of the company’s experimental Covid-19 vaccine in the United States after delaying the trial twice due to issues in scaling up the manufacturing process.

COVID-19 cases still surging in the Americas, the WHO warns BRASILIA (Reuters) – COVID-19 cases are still surging in the Americas, averaging 150,000 a day in last week, the World Health Organization’s regional office said on Wednesday. The United States continues to report record-breaking numbers, while parts of Canada and some states in Mexico, including […]

The Takeda Pharmaceutical Co.-led group that is developing a blood plasma treatment for Covid-19 started manufacturing while the late-stage trial to determine whether the hyperimmune globulin therapy works is ongoing, Chief Executive Christophe Weber said.